NasdaqGS:IBRXBiotechs
Assessing ImmunityBio (IBRX) Valuation After Anktiva Progress And Upcoming 2026 ASCO Presentation
ImmunityBio (IBRX) is back in focus after strong Anktiva revenue growth, accelerated approval in Saudi Arabia for a new bladder cancer use, and rising interest ahead of its 2026 ASCO Genitourinary Cancers Symposium presentation.
See our latest analysis for ImmunityBio.
Those Anktiva updates and fresh lymphoma trial plans have arrived alongside strong recent momentum, with a 30 day share price return of 134.75% and a year to date share price return of 227.72%. The 1 year total shareholder...